Aelis Farma: Green Light from Independent Committee to Continue Phase 2b of AEF0217
The biotech company from Bordeaux, Aelis Farma, has received a favorable opinion from the independent data monitoring committee to continue the phase 2b clinical trial of its candidate AEF0217, aimed at treating behavioral and cognitive disorders in individuals with Down syndrome.
Green Light from Monitoring Committee to Continue Study
The independent data monitoring committee has recommended continuing the phase 2b trial with AEF0217 in patients with Down syndrome. This positive opinion validates the clinical trajectory of the program and allows the company to maintain its schedule for evaluating the candidate in this therapeutic indication.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning
✓ Euronext data
✓ AI-powered analysis
Indicative data. No investment advice. Unsubscribe at any time.
Related
🏢
Other stocks — Santé
🗞️
Nanobiotix Shares Soar by 4.5%, Leading the SBF 120
🗞️
DBV Technologies Stock Plummets, Breaking Its €2.60 Support Following a Fundraising Project
🗞️
DBV Technologies: $150 Million ATM Program Filed with the SEC
🗞️
Advicenne: Net Revenue More Than Doubled to €2.7M in H1 2026
